CECAD Microsite

Curriculum Vitae

Education:

  • 1996-2003 Medical school, (Final grade: Sehr gut, highest honors), University of Hamburg, Germany; Humboldt University, Berlin, Germany; University of Freiburg, Germany.
  • 1999-2003 MD thesis, Department of Internal Medicine, Division 4, University of Freiburg. Entitled: Expression of functional CC- and CXC chemokine receptors in podocytes. Advisor: Prof. Dr. H. Pavenstädt (Grade: Summa cum laude, highest honors)

 

Professional Experience:

  • 01.10.2018 Speaker of the Mildred Scheel School of Oncology (Mildred Scheel Nachwuchszentrum) Cologne-Bonn
  • 01.04.2018 Member of the Expert Pool of the National Committee on Animal Welfare (TierSchG) within the Federal Institute of Risk Assessment (Bundesinstitut für Risikobewertung)
  • 01.06.2017 Executive attending physician of the Medical Clinic I of the University Hospital Cologne
  • 01.03.2017 Speaker of the Else Kröner Forschungskolleg: Clonal evolution in cancer
  • 01.01.2017 Vice speaker of the DKG-AEK-S (Systems Biology, Systems Medicine)
  • 01.09.2016 Attending physician responsible for finances and economic development of the Medical Clinic I of the University Hospital Cologne
  • 22.06.2016 Certified Clinical Trials Manager
  • 01.09.2015 Attending physician at the Medical Clinic I of the University Hospital Cologne
  • 28.05.2015  Board exam (certified in general internal medicine and hematology and medical oncology)
  • 31.01.2015 Elected member of the executive board of the Center for Molecular Medicine Cologne
  • 01.01.2013 Head of the Clinical Research Unit-286 “Exploiting defects in the DNA damage response for the treatment of chronic lymphocytic leukemia”
  • 01.01.2012 Scientific coordinator of Research Topic 3, Hematological Malignancies within the Helmholtz Preclinical Comprehensive Cancer Center
  • 01.06.2012 Scientific coordinator of Research Area C (DNA damage response) within the Excellence Cluster CECAD
  • 01.05.2012 Professor for Clinical and Molecular Oncology, University Hospital Cologne
  • 01.05. 2010 Certified Clinical Research Physician
  • Since 01.11.2009 Emmy-Noether research group leader at the Max-Planck-Institute Cologne and the Medical Clinic I of the University Hospital Cologne
  • 06.11.2009 Habilitation for Molecular Medicine at the Medical Faculty of the University of Cologne
  • 12.2004-11.2009 Postdoctoral Associate, MIT, Department of Biology, Koch Institute, Advisors: Profs. M.B. Yaffe, MD, PhD and T. Jacks, PhD
  • 01.01.-30.11.2004 Postdoctoral Research Fellow, University of Münster, Germany, Advisor: Prof. Dr. H. Pavenstädt.
  • 01.06.-31.12.2003 Postdoctoral Research Fellow University of Freiburg, Germany, Advisor: Profs. Dr. G. Walz and Dr. T. Benzing

 

Awards:

  • 2017: Gilead Research Award Oncology
  • 2016: Theodor Frerichs Award of the German Society for Internal Medicine
  • 2012: GlaxoSmithKline Research Award
  • 2011: Vincenz Czerny Award of the German Society for Hematology and Oncology
  • 2011: W2 Lichtenberg Professorship of the VolkswagenStiftung
  • 2011: CESAR Research Award of the Central European Society for Anticancer Drug Research
  • 2011: Johann-Georg-Zimmermann Award for Cancer Research
  • 2010: Young Leaders in Science Award of the Schering Stiftung
  • 2009: Emmy-Noether fellowship of the Deutsche Forschungsgemeinschaft
  • 2009: Startup grant from the Ministerium für Innovation, Wissenschaft, Forschung und Technologie des Landes NRW
  • 2009: NIH/NCI K99/R00 PI award (relinquished due to return to Germany)
  • 2009: Travel grant of the Deutsche Krebshilfe
  • 2007: MIT-Koch Award
  • 2005: Research fellowship of the Deutsche Forschungsgemeinschaft
  • 2004: Young investigator award of the Deutsche Nierenstiftung

 

Memberships:

  • Deutsche Gesellschaft für Innere Medizin
  • Deutsche Gesellschaft für Hämatologie und Onkologie
  • Deutsche Krebsgesellschaft
  • Deutsche Gesellschaft für DNA Reparaturforschung
  • Deutscher Hochschulverband
  • Kompetenznetz Maligne Lymphome
  • European Hematology Association
  • European Association for Cancer Research
  • European Society for Medical Oncology
  • American Association for Cancer Research
  • Central European Society for Anticancer Drug Research

 

10 Most Important Publications:

  1. Reinhardt HC, Aslanian AS, Lees JA, and Yaffe MB: p53 deficient cells rely on ATM and ATR-mediated checkpoint signaling through the p38 MAPK/MK2 pathway for survival after DNA damage. Cancer Cell, 2007 Feb;11(2):175-89. (IF: 27.407)
  2. Janes KA*, Reinhardt HC*, and Yaffe MB: Cytokine-induced signaling networks prioritize dynamic range over signal strength. Cell, 2008 Oct 17;135(2):343-54. *equal contribution (IF: 32.24)
  3. Jachimowicz RD, Beleggia F, Isensee J, Bhavana VB, Goergens J, Bustos MA, Doll MA, Shenoy A, Checa-Rodriguez C, Wiederstein JL, Baranes-Bachar K, Bartenhagen C, Hertwig F, Teper N, Nishi T, Schmitt A, Distelmaier F, Lüdecke HJ, Albrecht B, Krüger M, Schumacher B, Geiger T, Hoon DSB, Huertas P, Fischer M, Hucho T, Peifer M, Ziv Y, Reinhardt HC*,#, Wieczorek D*, Shiloh Y*: UBQLN4 represses homologous recombination and is overexpressed in aggressive tumors, Cell, 2018 Dec 21. pii: S0092-8674(18)31516-2. doi: 10.1016/j.cell.2018.11.024., * Shared last authors, # lead author contact (IF: 32.24)
  4. Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun A, Ozretić L, Künstlinger H, Kambartel K, Randerath WJ, Jüngst C, Schmitt A, Torgovnick A, Richters A, Rauh D, Siedek F, Persigehl T, Mauch C, Bartkova J, Bradley A, Sprick MR, Trumpp A, Rad R, Saur D, Bartek J, Wolf J, Büttner R, Thomas RK, Reinhardt HC: A synergistic interaction between Chk1- and MK2 inhibitors in KRAS-mutant cancer. Cell, 2015 Jul 2; 1; 146-159 (IF: 32.24)
  5. Dietlein F, Thelen L, Jokic M, Jachimowicz RD, Ivan L, Knittel G, Leeser U, van Oers J, Edelmann W, Heukamp LC, Reinhardt HC: A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discovery, Published Online First, 2014 Feb 20. (IF: 24.373)
  6. Riabinska A, Daheim M, Herter-Sprie GS, Winkler J, Fritz C, Hallek M, Thomas RK,   Kreuzer KA, Frenzel LP, Monfared P, Martins-Boucas JM, Chen S, Reinhardt HC: Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med, 2013 Jun 12;5(189):189ra78. doi: 10.1126/scitranslmed.3005814. (IF: 16.796)
  7. Knittel G, Rehkämper T, Korovkina D, Liedgens P, Fritz C, Torgovnick A, Al-Baldawi Y, Al-Maarri M, Cun Y, Fedorchenko O, Riabinska A, Beleggia F, Nguyen P-H, Wunderlich FT, Ortmann M, Montesinos-Rongen M, Tausch E, Stilgenbauer S, Frenzel L, Herling M, Herling C, Bahlo J, Hallek M, Peifer M, Büttner R, Persigehl T, Reinhardt HC: Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. Nature Communications, 2017 Jul 28;8(1):153. doi: 10.1038/s41467-017-00210-6. (IF: 12.353)
  8. Knittel G, Liedgens P, Korovkina D, Seeger JM, Al-Baldawi Y, Al-Maarri M, Fritz C, Vlantis K, Bezhanova S, Scheel AH, Wolz OO, Reimann M, Möller P, López C, Schlesner M, Lohneis P, Weber ANR, Trümper L, ICGC MMML-Seq Consortium, Staudt LM, Ortmann M, Pasparakis M, Siebert R, Schmitt CA, Klatt AR, Wunderlich FT, Schäfer SC, Persigehl T, Montesinos-Rongen M, Odenthal M, Büttner R, Frenzel LP, Kashkar H, Reinhardt HC: B cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B cell lymphoma in mice. Blood, 2016 Jun 2;127(22):2732-41. doi: 10.1182/blood-2015-11-684183. Epub 2016 Apr 5. (IF: 15.132)
  9. George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Leenders F, Lu X, Fernandez-Cuesta L, Bosco G, Nguyen C, Berg J, Müller C, Dahmen I, Jahchan N, Yang D, Karnezis AN, Vaka D, Torres A, Menon R, Wang MS, Stuetz A, Korbel J, Wilkerson M, Hayes N, Engelmann D, Pützer B, Vlasic I, Seidel D, Pinther B, Schaub B, Becker C, Altmüller J, Yokota J, Khono T, Iwakawa R, Muley T, Peterson I, Chen Y, Soltermann A, Tischler V, Massion P, Zou Y, Wright GM, Russell P, Solomon B, Koch I, Field JK, Muscarella LA, La Torre A, Jakopovic M, Knezevic J, Heiden E, Roz L, Jovanovic D, Kontic M, Thunnissen E, Köhler J, Schuler M, Sanchez-Cespedes M, Salvesen H, Achter V, Bogus M, Schneider P, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt HC, Perner S, Heukamp LC , Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK: Comprehensive genomic profiling of small cell lung cancer. Nature, 2015 Jul 13. doi: 10.1038/nature14664. [Epub ahead of print] (IF: 42.35)
  10. Wilker EW, van Vugt MA, Artim SA, Huang PH, Petersen CP, Reinhardt HC, Feng Y, Sharp PA, Sonenberg N, White FM, Yaffe MB.: 14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature. 2007 Mar 15;446(7133) (IF: 42.35)

 

Patents, accepted:     

  1. Inventors: Michael B. Yaffe, Isaac A. Manke, Daniel Lim, Hans Christian Reinhardt
    USPTO Application #: 20090010927
    Title: Mapkap kinase-2 as a specific target for blocking proliferation of p53-defective cells
    Abstract: The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, e.g., in patients having one or more p53-deficient cells, screening assays for identifying such compounds, and methods for treating such disorders.

 

Patents, submitted:

  1. Inventors: Hai Jiang, Hans Christian Reinhardt, Michael B. Yaffe, Michael T. Hemann
    USPTO Application #: Pending, application is being processed by the technology licensing office.
    Title: Inhibition of DNA-PKcs sensitizes ATM-deficient tumors to genotoxic chemotherapy
  2. Inventors: Hans Christian Reinhardt, Hai Jiang, Michael B. Yaffe, Michael T. Hemann
    USPTO Application #: Pending, application is being processed by the technology licensing office.
    Title: Use of ATM, Chk2 and p53 status to predict chemotherapeutic outcome
  3. Inventors: Hans Christian Reinhardt, Michael B. Yaffe, Isaac A. Manke, Daniel Lim
    USPTO Application #: Pending, application is being processed by the technology licensing office.
    Title: METHODS FOR DIAGNOSING AND TREATING CANCER
    File reference: 01997/570W02
Christian Reinhardt
Christian Reinhardt